L & S Advisors’s Guardant Health GH Stock Holding History

L & S Advisors’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.86M	Buy	+19,057	New	+$2.07M	0.3%	100
2021 Q3	–	Sell	-18,357	Closed	-$2.28M	–	356
2021 Q2	$2.28M	Buy	+18,357	New	+$2.47M	0.25%	127

Other funds holding GH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

L & S Advisors's GH Position: Q2 2026 in Review

L & S Advisors opened a new position in Guardant Health (GH) in Q2 2026: 19,057 shares worth $2.86M. The stake represents 0.3% of the portfolio and ranks #100 among its holdings. This is a return to the name: L & S Advisors previously reported a position in GH as recently as Q2 2021.

L & S Advisors first reported a position in GH in Q2 2021 and has held it in 2 quarters since. 598 funds tracked by Wall St. Rank hold GH as of Q2 2026.

L & S Advisors held 19,057 shares of Guardant Health worth $2.86M as of Q2 2026.
Guardant Health was a new L & S Advisors position in Q2 2026.
Guardant Health made up 0.3% of L & S Advisors's portfolio in Q2 2026, its #100 holding.
L & S Advisors first reported a position in Guardant Health in Q2 2021 and has held it in 2 quarters since.
598 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.

Based on L & S Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.